Knight Therapeutics (GUD) Sets New 1-Year Low at $7.22

Share on StockTwits

Knight Therapeutics Inc (TSE:GUD) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as C$7.22 and last traded at C$7.24, with a volume of 105833 shares changing hands. The stock had previously closed at C$7.36.

Separately, Raymond James reiterated an “outperform” rating and set a C$10.25 price objective on shares of Knight Therapeutics in a report on Wednesday, January 16th.

The firm has a market cap of $1.03 billion and a PE ratio of 42.80.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, March 14th. The company reported C$0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C$0.03 by C$0.01. The business had revenue of C$3.89 million for the quarter, compared to analyst estimates of C$2.55 million. Equities research analysts predict that Knight Therapeutics Inc will post 0.179999995108696 earnings per share for the current fiscal year.

In other Knight Therapeutics news, Director Jonathan Ross Goodman acquired 3,600 shares of Knight Therapeutics stock in a transaction dated Thursday, April 4th. The stock was purchased at an average cost of C$7.38 per share, for a total transaction of C$26,568.00. Following the completion of the acquisition, the director now directly owns 444,320 shares of the company’s stock, valued at C$3,279,081.60.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at

Knight Therapeutics Company Profile (TSE:GUD)

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Featured Story: How do candlesticks reflect price movement?

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.